GO:0050428 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process: PAPS Synthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050428 describes the biosynthesis of 3'-phosphoadenosine 5'-phosphosulfate (PAPS), the universal sulfate donor for all sulfotransferase reactions.
• PAPS is synthesized in two sequential enzymatic steps: ATP sulfurylase converts ATP and sulfate to APS, and APS kinase phosphorylates APS to PAPS.
• PAPS biosynthesis is essential for sulfation of hormones, neurotransmitters, xenobiotics, and structural macromolecules such as glycosaminoglycans.
• PAPS levels allosterically regulate sulfotransferase turnover, linking sulfate donor availability to detoxification capacity.
• Inhibition of p53 sulfoconjugation via PAPS depletion prevents oxidative hepatotoxicity and acute liver failure in preclinical models.
• CRISPR knockout, point-mutation, and knock-in models of PAPS pathway genes enable causal dissection of sulfation in disease and development.
Description
3'-Phosphoadenosine 5'-phosphosulfate (PAPS) is a naturally occurring mixed anhydride that serves as the obligate sulfate donor for all sulfotransferase-catalyzed reactions in eukaryotes and prokaryotes. The biosynthetic process that produces PAPS, annotated as GO:0050428, is therefore a central metabolic node that supplies activated sulfate for the modification of thousands of acceptor molecules, including hormones, neurotransmitters, drugs, and extracellular matrix components. Because sulfation alters the biological activity, solubility, and half-life of these acceptors, PAPS biosynthesis directly influences endocrine signaling, xenobiotic detoxification, and tissue homeostasis. Research over the past four decades has defined the enzymatic steps, regulatory features, and disease associations of PAPS biosynthesis. The pathway begins with ATP sulfurylase, which activates inorganic sulfate by forming adenosine 5'-phosphosulfate (APS), and concludes with APS kinase, which phosphorylates APS at the 3'-position to yield PAPS. In humans, PAPS synthase (PAPSS) enzymes catalyze both reactions, and genetic deficiency of PAPSS2 causes skeletal and endocrine abnormalities. PAPS levels are also modulated by the bifunctional enzyme 3'(2'),5'-bisphosphate nucleotidase, which degrades PAPS and related nucleotides. For researchers, GO:0050428 provides a precise ontological handle for interrogating how cells allocate sulfate to competing metabolic fates. The pathway intersects with oxidative stress responses, drug metabolism, and developmental signaling, making it a compelling target for CRISPR-based functional genomics. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to outline the mechanism, key genes, disease relevance, and experimental strategies for studying PAPS biosynthesis.
3'-phosphoadenosine 5'-phosphosulfate biosynthetic process At A Glance
| GO ID | GO:0050428 |
|---|---|
| GO term | 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process |
| Ontology | biological_process |
| Synonym | PAPS biosynthesis; PAPS biosynthetic process; 3'-phosphoadenylyl-sulfate biosynthesis; adenosine 3'-phosphate 5'-phosphosulfate biosynthesis; phosphoadenosine phosphosulfate biosynthesis |
| Major function | Production of PAPS, the universal sulfate donor for sulfotransferase reactions |
| Key enzymes | ATP sulfurylase, APS kinase, PAPS synthase (PAPSS1/PAPSS2), 3'(2'),5'-bisphosphate nucleotidase |
| Substrates | ATP, inorganic sulfate, APS |
| Product | 3'-Phosphoadenosine 5'-phosphosulfate (PAPS) |
| Pathway context | Sulfur metabolism; sulfation; xenobiotic detoxification; hormone inactivation |
What Is GO:0050428?
GO:0050428, 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process, is defined by QuickGO as the chemical reactions and pathways resulting in the formation of 3'-phosphoadenosine 5'-phosphosulfate, a naturally occurring mixed anhydride that serves as an intermediate in the formation of a variety of sulfo compounds in biological systems. In practical terms, it encompasses the enzymatic conversion of ATP and inorganic sulfate into PAPS, the high-energy sulfate donor required for all sulfotransferase reactions.
Why Is 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process Important in Cell Biology?
PAPS biosynthesis is important because it supplies the sole activated sulfate donor used by sulfotransferases to modify hormones, neurotransmitters, drugs, and structural macromolecules. Without PAPS, sulfation of cholecystokinin, p53, and glycosaminoglycans cannot proceed, disrupting endocrine signaling, tumor suppressor regulation, and extracellular matrix integrity. PAPS levels also allosterically regulate sulfotransferase turnover, meaning the biosynthetic pathway sets the tempo for detoxification and metabolic clearance. Consequently, genetic or pharmacological perturbation of GO:0050428 has broad physiological consequences, from skeletal dysplasia to acute liver failure.
• PAPS is the obligate sulfate donor for all sulfotransferase reactions, making its biosynthesis essential for sulfation of hormones, neurotransmitters, and xenobiotics.
• PAPS biosynthesis regulates the sulfation of cholecystokinin, a neuropeptide involved in satiety and anxiety, in rat brain tissue.
• Inhibition of p53 sulfoconjugation through PAPS depletion prevents oxidative hepatotoxicity and acute liver failure in mice.
• PAPS allosterically regulates sulfotransferase turnover, coupling sulfate donor availability to detoxification capacity.
• Genetic deficiency of PAPS synthase causes skeletal and endocrine abnormalities in humans.
• 3'(2'),5'-Bisphosphate nucleotidase degrades PAPS and related nucleotides, providing a counterbalance to biosynthesis.
• Sulfated plant peptide hormones depend on PAPS biosynthesis for growth and defense signaling, highlighting evolutionary conservation.
• PAPS biosynthesis is a target for metabolic engineering of sulfated compounds in biotechnology.
• Dysregulated PAPS biosynthesis has been implicated in oxidative stress responses and drug-induced liver injury.
• CRISPR screens targeting PAPS pathway genes can identify causal roles in sulfation-dependent phenotypes.
What Happens During 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process?
Step 1: Sulfate Activation by ATP Sulfurylase
In simple terms: The cell uses energy from ATP to attach sulfate to a carrier molecule, forming APS.
The first committed step of PAPS biosynthesis is catalyzed by ATP sulfurylase, which condenses inorganic sulfate with ATP to form adenosine 5'-phosphosulfate (APS) and pyrophosphate. This reaction activates sulfate by creating a mixed anhydride bond, raising its free energy for subsequent transfer reactions. In humans, ATP sulfurylase activity resides in the bifunctional PAPS synthase enzymes PAPSS1 and PAPSS2, which couple sulfate activation to APS phosphorylation. The reaction requires magnesium ions and is reversible under physiological conditions, but subsequent APS consumption drives flux toward PAPS.
Step 2: Phosphorylation of APS to PAPS by APS Kinase
In simple terms: APS is phosphorylated at the 3'-position to produce PAPS, the final sulfate donor.
APS kinase catalyzes the ATP-dependent phosphorylation of APS at the 3'-hydroxyl of the ribose moiety, yielding PAPS and ADP. This second step is irreversible and commits the pathway to PAPS production. In humans, APS kinase activity is also part of the bifunctional PAPSS1 and PAPSS2 proteins, ensuring efficient channeling of APS to PAPS. The reaction consumes a second molecule of ATP, making PAPS biosynthesis energetically expensive and tightly regulated.
Step 3: PAPS Utilization and Sulfate Transfer
In simple terms: PAPS donates its sulfate group to acceptor molecules, releasing PAP.
PAPS serves as the sulfate donor for sulfotransferase enzymes, which transfer the sulfonate group to hydroxyl or amino groups on acceptor substrates such as hormones, neurotransmitters, drugs, and glycosaminoglycans. This transfer releases 3'-phosphoadenosine 5'-phosphate (PAP), which must be degraded to prevent product inhibition. The sulfation reaction alters the biological activity, solubility, and half-life of the acceptor, thereby linking PAPS biosynthesis to diverse physiological processes.
Step 4: Degradation of PAP and PAPS by 3'(2'),5'-Bisphosphate Nucleotidase
In simple terms: A phosphatase enzyme removes phosphate groups from PAP and PAPS to recycle nucleotides and prevent buildup.
3'(2'),5'-Bisphosphate nucleotidase (also known as bisphosphate nucleotidase) hydrolyzes PAP and PAPS to AMP and inorganic phosphate, thereby preventing accumulation of these inhibitory nucleotides. This enzyme is sensitive to lithium and is thought to play a role in the therapeutic and toxic effects of lithium salts. By degrading PAP, the enzyme relieves product inhibition of sulfotransferases and maintains flux through the PAPS biosynthetic pathway.
Step 5: Allosteric Regulation of Sulfotransferase Turnover by PAPS
In simple terms: PAPS itself can bind to sulfotransferases and control how quickly they are degraded.
PAPS acts as an allosteric regulator of sulfotransferase turnover, binding to the enzyme and influencing its stability and degradation. This feedback mechanism couples the rate of PAPS biosynthesis to the cellular capacity for sulfation, ensuring that sulfate donor supply matches demand. When PAPS levels are low, sulfotransferases may be stabilized or degraded differently, affecting overall detoxification capacity. This regulatory layer adds complexity to the pathway and highlights the importance of measuring PAPS flux in experimental systems.
Key Genes Involved in GO:0050428 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process
The following genes and proteins are directly involved in or regulate the 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process (GO:0050428).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAPSS1 | Bifunctional ATP sulfurylase/APS kinase; synthesizes PAPS | Major PAPS synthase isoform in most tissues; target for knockout and knockdown studies |
| PAPSS2 | Bifunctional ATP sulfurylase/APS kinase; synthesizes PAPS | Genetic deficiency causes skeletal and endocrine abnormalities; disease model |
| BPNT1 | 3'(2'),5'-bisphosphate nucleotidase; degrades PAP and PAPS | Regulates PAPS levels and sulfotransferase activity; lithium sensitivity |
| SULT1A1 | Sulfotransferase; utilizes PAPS to sulfate small molecules | Model for PAPS-dependent detoxification and hormone metabolism |
| SULT1E1 | Sulfotransferase; sulfates estrogens | Endocrine regulation; PAPS supply affects estrogen inactivation |
| SULT2A1 | Sulfotransferase; sulfates bile acids and steroids | Liver-specific sulfation; linked to hepatotoxicity |
| TPST1 | Tyrosylprotein sulfotransferase; sulfates cholecystokinin | Neuropeptide processing; PAPS-dependent |
| TPST2 | Tyrosylprotein sulfotransferase; sulfates proteins | Protein sulfation; PAPS-dependent |
| CHST1 | Carbohydrate sulfotransferase; sulfates keratan | Extracellular matrix sulfation; PAPS-dependent |
| CHST3 | Carbohydrate sulfotransferase; sulfates chondroitin | Skeletal development; PAPS-dependent |
| UST | Uronyl 2-sulfotransferase; sulfates glycosaminoglycans | Matrix assembly; PAPS-dependent |
| PAPSS1/2 | Bifunctional enzymes; channel APS to PAPS | Gene editing to dissect isoform-specific functions |
| SLC26A1 | Sulfate transporter; supplies sulfate for PAPS synthesis | Sulfate availability limits PAPS production |
| SLC13A1 | Sodium-sulfate cotransporter; sulfate uptake | Regulates intracellular sulfate pool |
| p53 | Tumor suppressor; sulfoconjugated in a PAPS-dependent manner | PAPS depletion prevents p53 sulfation and hepatotoxicity |
| CCK | Cholecystokinin; sulfated by TPST using PAPS | Neuropeptide function; PAPS-dependent |
| PSK | Phytosulfokine; sulfated plant peptide hormone | Plant growth signaling; PAPS-dependent |
| RGF | Root growth factor; sulfated plant peptide | Plant development; PAPS-dependent |
How Is 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process Regulated?
PAPS biosynthesis is regulated at multiple levels. The bifunctional PAPS synthase enzymes PAPSS1 and PAPSS2 are subject to transcriptional and post-transcriptional control, and their activity is influenced by sulfate availability through transporters such as SLC26A1 and SLC13A1. PAPS levels allosterically regulate sulfotransferase turnover, creating a feedback loop that matches sulfate donor supply to demand. Additionally, 3'(2'),5'-bisphosphate nucleotidase degrades PAP and PAPS, preventing product inhibition and maintaining pathway flux. In plant systems, sulfated peptide hormones such as PSK and RGF depend on PAPS biosynthesis, and their signaling is modulated by environmental and developmental cues. In mammalian liver, oxidative stress and p53 activation can influence PAPS-dependent sulfation, linking redox status to pathway regulation.
3'-phosphoadenosine 5'-phosphosulfate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAPSS2 | Skeletal dysplasia, endocrine abnormalities | Knockout mouse, patient-derived iPSCs |
| p53 | Acute liver failure, oxidative hepatotoxicity | Liver-specific knockout, point-mutation knock-in |
| BPNT1 | Lithium sensitivity, PAPS degradation | Knockout cell lines, enzymatic assays |
| TPST1/TPST2 | Neuropeptide dysfunction, cholecystokinin processing | Neuronal knockout, sulfation assays |
| SULT2A1 | Bile acid and steroid sulfation, hepatotoxicity | Hepatocyte knockout, overexpression |
PAPS Biosynthesis and Skeletal Dysplasia
Genetic deficiency of PAPSS2, the bifunctional enzyme that catalyzes both steps of PAPS biosynthesis, causes skeletal and endocrine abnormalities in humans. Loss of PAPS production impairs sulfation of glycosaminoglycans such as chondroitin sulfate, leading to defective cartilage and bone development. This condition highlights the non-redundant role of PAPS biosynthesis in connective tissue biology and provides a monogenic model for studying the pathway.
PAPS Depletion and Acute Liver Failure
Inhibition of p53 sulfoconjugation through PAPS depletion prevents oxidative hepatotoxicity and acute liver failure in preclinical models. PAPS-dependent sulfation of p53 modulates its activity, and blocking this modification protects against liver injury. This finding links PAPS biosynthesis to redox stress responses and suggests that modulating the pathway could be therapeutic in acute liver failure.
PAPS Biosynthesis in Neuropeptide Processing
PAPS biosynthesis is required for the sulfation of cholecystokinin by tyrosylprotein sulfotransferase in rat brain tissue. Sulfated cholecystokinin is the biologically active form that regulates satiety, anxiety, and gut function. Dysregulation of PAPS production could therefore impact neuropeptide signaling and related behavioral or metabolic disorders.
PAPS Biosynthesis and Xenobiotic Detoxification
PAPS is the sulfate donor for sulfotransferase-mediated detoxification of drugs, hormones, and environmental chemicals. Reduced PAPS availability can impair clearance of xenobiotics and increase susceptibility to toxicity. PAPS allosterically regulates sulfotransferase turnover, further linking the biosynthetic pathway to detoxification capacity.
From 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PAPSS1 loss reduce PAPS levels and sulfation? | CRISPR knockout in HEK293 or HepG2 cells |
| Does a PAPSS2 point mutation cause skeletal defects? | Knock-in mouse or patient iPSC-derived chondrocytes |
| Does PAPS depletion prevent p53 sulfation? | Liver-specific knockout or point-mutation knock-in |
| Can PAPS biosynthesis be enhanced to improve detoxification? | Overexpression of PAPSS1/2 in hepatocytes |
| How does PAPS allosterically regulate sulfotransferase turnover? | Tagged knock-in of SULT with degradation reporters |
| What genes are essential for PAPS-dependent sulfation? | CRISPR library screening in sulfation reporter cells |
How to Study the 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | PAPS and APS levels | Quantifying pathway activity in cells and tissues |
| Radioactive sulfate incorporation | Flux through PAPS biosynthesis | Enzymatic assays in lysates |
| Sulfotransferase activity assay | Sulfated product formation | Testing PAPS-dependent sulfation |
| CRISPR knockout screening | Gene essentiality for PAPS production | Identifying novel pathway regulators |
| RNA-seq | Transcriptional changes in PAPS pathway genes | Evaluating compensatory responses |
| Proteomics | Protein expression of PAPSS and SULTs | Validating knockout or overexpression |
| Metabolic labeling | Sulfate incorporation into macromolecules | Measuring glycosaminoglycan sulfation |
| Enzymatic assays | ATP sulfurylase and APS kinase activity | Characterizing mutant enzymes |
Measuring PAPS Levels and Flux
Quantification of PAPS and APS by LC-MS/MS or HPLC is the gold standard for assessing pathway activity. Radioactive sulfate incorporation assays can measure flux through PAPS biosynthesis in cell lysates. These methods are essential for validating CRISPR knockout or overexpression phenotypes.
Sulfotransferase Activity Assays
Sulfotransferase activity can be measured using radiolabeled PAPS or by detecting sulfated products via mass spectrometry. These assays link PAPS biosynthesis to downstream sulfation of hormones, drugs, and proteins. They are useful for testing whether genetic perturbations alter sulfate transfer.
CRISPR Screening for PAPS Pathway Genes
Genome-wide CRISPR knockout or activation screens can identify genes that regulate PAPS levels or sulfation-dependent phenotypes. Reporter cells expressing sulfation-sensitive fluorescent proteins enable high-throughput screening. Hits can be validated by targeted knockout and metabolic profiling.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in PAPSS1, PAPSS2, BPNT1, and sulfotransferase expression upon pathway perturbation. These approaches help identify compensatory mechanisms and regulatory networks. Integrating multi-omics data with PAPS measurements provides a systems-level view.
How CRISPR Can Be Used to Study GO:0050428 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process
Knockout
CRISPR knockout of PAPSS1, PAPSS2, or BPNT1 can abolish or reduce PAPS biosynthesis, enabling studies of sulfation-dependent phenotypes. Knockout cell lines are useful for measuring PAPS levels, sulfotransferase activity, and downstream effects on hormone signaling or detoxification. Liver-specific knockout of p53 sulfation regulators has been used to model acute liver failure.
Point Mutation
Point mutations in PAPSS2 identified in patients with skeletal dysplasia can be introduced into cell lines or mice to dissect structure-function relationships. Catalytic dead mutants of ATP sulfurylase or APS kinase can separate the two steps of PAPS biosynthesis. Point mutations in sulfotransferases can reveal residues required for PAPS binding and turnover.
Knock-in
Tagged knock-in of PAPSS1, PAPSS2, or SULT enzymes with fluorescent or affinity tags allows real-time tracking of protein localization and turnover. Knock-in of disease-associated PAPSS2 variants creates isogenic models for drug testing. Knock-in reporters for PAPS levels can be used in high-throughput screens.
Overexpression
Overexpression of PAPSS1 or PAPSS2 can increase PAPS production and enhance sulfation capacity in cells. This approach is useful for studying the effects of excess PAPS on sulfotransferase activity and detoxification. Overexpression in plant systems can boost sulfated peptide hormone production.
How EDITGENE Supports 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process Research
Researchers studying 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in PAPS production, sulfation, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible interrogation of the pathway from gene to function.
Contact EDITGENE today to design your custom CRISPR model for 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process research.
Frequently Asked Questions About 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process
What is 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process?
It is the metabolic pathway (GO:0050428) that produces PAPS, the universal sulfate donor for sulfotransferase reactions, from ATP and inorganic sulfate.
What genes are involved in PAPS biosynthesis?
Key genes include PAPSS1, PAPSS2, BPNT1, and sulfate transporters such as SLC26A1 and SLC13A1.
What is the function of PAPS in cells?
PAPS donates sulfate groups to hormones, neurotransmitters, drugs, and macromolecules, altering their activity and clearance.
How is PAPS synthesized?
ATP sulfurylase converts ATP and sulfate to APS, and APS kinase phosphorylates APS to PAPS, both activities residing in bifunctional PAPSS enzymes.
What diseases are linked to PAPS biosynthesis defects?
PAPSS2 deficiency causes skeletal dysplasia and endocrine abnormalities, and PAPS depletion can prevent p53-dependent acute liver failure.
How can I study PAPS biosynthesis using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models of PAPSS1/2 and BPNT1 allow causal testing of pathway function.
What is the role of BPNT1 in PAPS metabolism?
BPNT1 degrades PAP and PAPS, preventing product inhibition and regulating sulfotransferase activity.
Is PAPS biosynthesis conserved in plants?
Yes, sulfated plant peptide hormones such as PSK and RGF depend on PAPS biosynthesis for growth and defense signaling.
How does PAPS regulate sulfotransferase turnover?
PAPS allosterically binds sulfotransferases and influences their stability and degradation, coupling donor supply to detoxification capacity.
What methods measure PAPS levels?
LC-MS/MS, radioactive sulfate incorporation, and sulfotransferase activity assays are commonly used to quantify PAPS and pathway flux.
Conclusion
GO:0050428, 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process, is a fundamental metabolic pathway that supplies the universal sulfate donor PAPS for sulfation of hormones, neurotransmitters, drugs, and structural macromolecules. Its two-step enzymatic mechanism, mediated by bifunctional PAPSS enzymes and counterbalanced by BPNT1, is conserved across eukaryotes and essential for skeletal, endocrine, and hepatic physiology. Dysregulation of PAPS biosynthesis contributes to skeletal dysplasia, acute liver failure, and impaired xenobiotic detoxification, making it a compelling target for CRISPR-based functional studies. Researchers can leverage knockout, point-mutation, knock-in, and overexpression models to dissect the causal roles of PAPS pathway genes in health and disease. EDITGENE provides end-to-end CRISPR cell model and screening services to accelerate these discoveries.
References
- 1. Ramaswamy SG et al.. 1987. (2')3',5'-Bisphosphate nucleotidase.. J Biol Chem 262(21):10044-7 PMID: 3038862
- 2. Venkatachalam KV. 2003. Human 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase: biochemistry, molecular biology and genetic deficiency.. IUBMB Life 55(1):1-11 PMID: 12716056
- 3. Zhou Z et al.. 2019. [Production and application of 3-phosphoadenosine-5- phosphosulfate].. Sheng Wu Gong Cheng Xue Bao 35(7):1222-1233 PMID: 31328479
- 4. Xu P et al.. 2022. Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure.. Gastroenterology 162(4):1226-1241 PMID: 34954226
- 5. Vargas F et al.. 1994. 3'-Phosphoadenosine 5'-phosphosulfate biosynthesis and the sulfation of cholecystokinin by the tyrosylprotein-sulfotransferase in rat brain tissue.. Chem Biol Interact 92(1-3):281-91 PMID: 8033261
- 6. Kaufmann C et al.. 2019. Sulfated plant peptide hormones.. J Exp Bot 70(16):4267-4277 PMID: 31231771
- 7. Klaassen CD et al.. 1997. Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation.. FASEB J 11(6):404-18 PMID: 9194521
- 8. Wang T et al.. 2014. 3'-Phosphoadenosine 5'-phosphosulfate allosterically regulates sulfotransferase turnover.. Biochemistry 53(44):6893-900 PMID: 25314023
